- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 8th, 2007
Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National Cancer Institute (NCI).
The Florida-based company will use its proprietary NanoDRY drug delivery technology to develop the peptide vaccine candidate into an oral form which will have targeted delivery to the lower gastrointestinal (GI) tract.
|Related News Press|
New remote-controlled microrobots for medical operations July 23rd, 2016
New probe developed for improved high resolution measurement of brain temperature: Improved accuracy could allow researchers to measure brain temperature in times of trauma when small deviations in temperature can lead to additional brain injury July 23rd, 2016